Bivalirudin Evidence Guide
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
Our Take
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
- Evidence context
- PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.75mg/kg IV bolus then 1.75mg/kg/hour infusion during PCI
Benefits and Evidence
- PCI Anticoagulation: Level A, includes human evidence - Multiple large RCTs demonstrate effective anticoagulation during PCI with reduced bleeding compared to heparin plus GP IIb/IIIa inhibitors.
- Reduced Major Bleeding: Level A, includes human evidence - HORIZONS-AMI and other trials consistently show significant reduction in major bleeding events compared to heparin-based regimens.
- Acute Stent Thrombosis: Level A, includes human evidence - Slightly increased risk of acute stent thrombosis within 24 hours compared to heparin, likely due to rapid offset. Mitigated by post-PCI infusion protocols.
Side Effects and Warnings
- Bleeding
- Back pain
- Nausea
- Hypotension
- Headache
- Renal dose adjustment required - predominantly cleared renally
- Increased stent thrombosis risk if infusion stopped abruptly
- No specific reversal agent available
Research Dosage References
- <strong>Intravenous bolus + infusion</strong> - 0.75 mg/kg bolus, then 1.75 mg/kg/h - During PCI, continued for up to 4 hours post-procedure - ACT should be checked 5 minutes after bolus. Additional bolus of 0.3 mg/kg if ACT <225 seconds. Reduce infusion to 1 mg/kg/h with GFR <30 mL/min.
- <strong>Intravenous infusion</strong> - 0.15-0.2 mg/kg/h - Continuous (for HIT patients) - Used as anticoagulant in patients with heparin-induced thrombocytopenia. Titrate to aPTT 1.5-2.5x control.
Mechanism of Action
Bivalirudin provides anticoagulation through direct, bivalent thrombin inhibition: 1. Bivalent thrombin binding: Simultaneously binds to the catalytic active site and the anion-binding exosite 1 of thrombin. 2. Reversible inhibition: Thrombin slowly cleaves the Arg3-Pro4 bond of bivalirudin, allowing recovery of thrombin active site function - providing a self-regulating mechanism. 3. Clot-bound thrombin inhibition: Unlike heparin, bivalirudin directly inhibits both free and clot-bound thrombin, providing more complete anticoagulation. 4. No platelet activation: Does not require antithrombin III as a cofactor and does not activate platelets (unlike heparin), reducing risk of heparin-induced thrombocytopenia.
Legal Status
FDA-approved for use as an anticoagulant in patients undergoing PCI and for patients with or at risk of HIT undergoing PCI. Available by prescription for hospital use. Marketed as Angiomax by The Medicines Company. Generic versions available.
Primary Sources
- Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI). N Engl J Med, 2008.
- Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI (EUROMAX). N Engl J Med, 2013.
- Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: a meta-analysis. Eur Heart J, 2015.
Quick Answers
Where is the strongest evidence for Bivalirudin?
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings. Evidence context: PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research.
What are the main side effects of Bivalirudin?
Bivalirudin side effects and warning signals include Bleeding, Back pain, Nausea, Hypotension, and Headache.
What evidence level is Bivalirudin?
Bivalirudin is rated Level A; the listed research status is FDA Approved.